CreativeOne Wealth LLC Boosts Stake in Lantheus Holdings, Inc. $LNTH

CreativeOne Wealth LLC raised its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 26.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 20,396 shares of the medical equipment provider’s stock after acquiring an additional 4,316 shares during the quarter. CreativeOne Wealth LLC’s holdings in Lantheus were worth $1,670,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Nuveen LLC bought a new stake in Lantheus during the first quarter valued at about $55,941,000. Epoch Investment Partners Inc. purchased a new stake in shares of Lantheus during the first quarter valued at about $35,548,000. Mackenzie Financial Corp boosted its holdings in shares of Lantheus by 129.2% in the 1st quarter. Mackenzie Financial Corp now owns 497,437 shares of the medical equipment provider’s stock valued at $48,550,000 after buying an additional 280,381 shares in the last quarter. Nitorum Capital L.P. bought a new stake in shares of Lantheus in the 1st quarter valued at about $23,261,000. Finally, Reinhart Partners LLC. grew its position in shares of Lantheus by 16.4% in the 2nd quarter. Reinhart Partners LLC. now owns 1,403,659 shares of the medical equipment provider’s stock worth $114,905,000 after buying an additional 197,719 shares during the last quarter. 99.06% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently commented on LNTH shares. B. Riley decreased their target price on shares of Lantheus from $109.00 to $84.00 and set a “buy” rating for the company in a research report on Tuesday, September 16th. Truist Financial reiterated a “hold” rating and set a $61.00 price objective (down previously from $63.00) on shares of Lantheus in a report on Monday, November 10th. Mizuho dropped their target price on Lantheus from $120.00 to $70.00 and set an “outperform” rating on the stock in a research note on Thursday, August 7th. JMP Securities reduced their target price on Lantheus from $112.00 to $73.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 7th. Finally, Weiss Ratings cut Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Saturday, October 25th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $74.17.

Lantheus Trading Down 0.5%

Lantheus stock opened at $58.75 on Thursday. The stock has a 50-day moving average price of $54.28 and a 200 day moving average price of $64.44. The company has a market capitalization of $3.90 billion, a price-to-earnings ratio of 15.63 and a beta of 0.04. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $111.29. The company has a quick ratio of 4.07, a current ratio of 4.29 and a debt-to-equity ratio of 0.49.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Tuesday, May 17th. The medical equipment provider reported $0.05 EPS for the quarter. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The business had revenue of $92.51 million during the quarter. Sell-side analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.